Atrium Therapeutics, Inc.
HealthcareNASDAQ:RNA · NASDAQ Global Select
-$0.06 today
Vol 0.10M · Avg 0.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.0%
avg -37.0%
ROIC
-31.9%
avg -31.9%
ROA
-27.5%
avg -27.5%
Analysis
ROA is currently the strongest return metric at -27.5% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Husam Younis | Chief Scientific Officer | — | — | 52 | — | — |
Brendan Winslow | Chief Financial Officer | — | — | 38 | — | — |
Steven George Hughes | Chief Medical Officer | — | — | 58 | — | — |
Kathleen Gallagher | President, CEO & Director | — | — | 44 | — | — |
Rocio Martin Hoyos | Chief Strategy Officer | — | — | 43 | — | — |
Stephanie Kenney | Chief Corporate Affairs Officer | — | — | 48 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +0.0% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +0.0% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages RNA?
Atrium Therapeutics, Inc. (RNA) lists 6 active executives. The top listed executive is Husam Younis, Chief Scientific Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.